Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $236,883 - $299,725
-2,205 Closed
0 $0
Q2 2021

Jul 27, 2021

SELL
$105.21 - $117.21 $77,750 - $86,618
-739 Reduced 25.1%
2,205 $248,000
Q4 2020

Feb 11, 2021

BUY
$80.49 - $108.67 $236,962 - $319,924
2,944 New
2,944 $315,000
Q3 2020

Nov 13, 2020

SELL
$85.91 - $100.83 $6.7 Million - $7.86 Million
-77,985 Closed
0 $0
Q2 2020

Aug 06, 2020

SELL
$73.37 - $98.18 $2.56 Million - $3.42 Million
-34,852 Reduced 30.89%
77,985 $7.66 Million
Q1 2020

May 12, 2020

SELL
$64.5 - $97.79 $190,275 - $288,480
-2,950 Reduced 2.55%
112,837 $8.6 Million
Q4 2019

Jan 21, 2020

BUY
$72.13 - $90.25 $1.09 Million - $1.37 Million
15,125 Added 15.03%
115,787 $10.3 Million
Q3 2019

Nov 01, 2019

BUY
$62.98 - $75.72 $650,394 - $781,960
10,327 Added 11.43%
100,662 $7.62 Million
Q2 2019

Jul 25, 2019

BUY
$65.7 - $83.98 $5.94 Million - $7.59 Million
90,335 New
90,335 $6.57 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Coronation Fund Managers Ltd. Portfolio

Follow Coronation Fund Managers Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Coronation Fund Managers Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Coronation Fund Managers Ltd. with notifications on news.